COVID-19疫苗接种后绝对淋巴细胞计数与18F-FDG PET/CT上疫苗诱导的高代谢淋巴结相关:聚焦乳腺癌诊疗
这项回顾性单中心研究纳入2021年3月初至4月底接种COVID-19疫苗后行18F-FDG PET/CT的260例患者(80%女性,56%乳腺癌),35%出现疫苗诱导的高代谢淋巴结(v-HLN),中位SUVmax 3.7。多因素分析显示年龄≤50岁、无淋巴细胞减少、距末次接种<30天为v-HLN独立因素;乳腺癌患者中仅无淋巴细胞减少为独立因素。作者认为正常绝对淋巴细胞计数者更易出现v-HLN,二者可能均与更强免疫应答相关。
要点
- 接种COVID-19疫苗后35%(90/260)患者出现v-HLN,中位SUVmax 3.7(范围2.0-26.3)。
- 年龄≤50岁、无淋巴细胞减少、距末次接种<30天为v-HLN独立因素。
- 乳腺癌患者中仅无淋巴细胞减少与v-HLN独立相关(OR 2.9;95%CI 1.2-7.4)。
核心结论
- 接种COVID-19疫苗后绝对淋巴细胞计数正常者更易在18F-FDG PET/CT上出现v-HLN,二者可能均与更强的疫苗免疫应答相关。
研究设计与样本
- 回顾性单中心研究,连续纳入2021年3月初至4月底接种信使RNA或病毒载体COVID-19疫苗后行18F-FDG PET/CT的患者260例,其中女性209例(80%)、乳腺癌145例(56%),中位年龄50岁(范围23-96岁)。
主要发现
- 90例(35%)患者出现v-HLN,中位SUVmax 3.7(范围2.0-26.3);74例(44%)存在淋巴细胞减少,中位绝对淋巴细胞计数1.4×10^9/L(范围0.3-18.3×10^9/L)。
- 233例(90%)接种信使RNA疫苗。
- 多因素分析中,年龄≤50岁(OR 2.2;95%CI 1.0-4.5)、无淋巴细胞减少(OR 2.2;95%CI 1.1-4.3)、距末次疫苗注射至18F-FDG PET/CT<30天(OR 2.6;95%CI 1.3-5.6)为v-HLN的独立因素。
- 乳腺癌患者中,无淋巴细胞减少是唯一与v-HLN显著相关的独立因素(OR 2.9;95%CI 1.2-7.4)。
临床怎么用
- 作者认为,接种COVID-19疫苗后绝对淋巴细胞计数正常者更易出现v-HLN,二者可能均与更强的疫苗免疫应答相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
We aimed to predict the presence of vaccine-induced hypermetabolic lymph nodes (v-HLNs) on 18F-FDG PET/CT after coronavirus disease 2019 (COVID-19) vaccination and determine their association with lymphocyte counts. Methods: In this retrospective single-center study, we included consecutive patients who underwent 18F-FDG PET/CT imaging after messenger RNA- or viral vector-based COVID-19 vaccination between early March and late April 2021. Demographics, clinical parameters, and absolute lymphocyte count (ALC) were collected, and their association with the presence of v-HLNs in the draining territory was studied by logistic regression. Results: In total, 260 patients were eligible, including 209 (80%) women and 145 (56%) with breast cancer. The median age was 50 y (range, 23-96 y). The messenger RNA vaccine had been given to 233 (90%). Ninety (35%) patients had v-HLNs, with a median SUVmax of 3.7 (range, 2.0-26.3), and 74 (44%) displayed lymphopenia, with a median ALC of 1.4 × 109/L (range, 0.3-18.3 × 109/L). An age of no more than 50 y (odds ratio [OR], 2.2; 95% CI, 1.0-4.5), the absence of lymphopenia (OR, 2.2; 95% CI, 1.1-4.3), and less than a 30-d interval from the last vaccine injection to the 18F-FDG PET/CT (OR, 2.6; 95% CI, 1.3-5.6) were independent factors for v-HLNs on multivariate analysis. In breast cancer patients, the absence of lymphopenia was the only independent factor significantly associated with v-HLNs (OR, 2.9; 95% CI, 1.2-7.4). Conclusion: Patients with a normal ALC after COVID-19 vaccination were more likely to have v-HLNs on 18F-FDG PET/CT, both of which might be associated with a stronger immune response to vaccination.
引用
- Seban RD, Richard C, Nascimento-Leite C, et al. Absolute Lymphocyte Count After COVID-19 Vaccination Is Associated with Vaccine-Induced Hypermetabolic Lymph Nodes on 18F-FDG PET/CT: A Focus in Breast Cancer Care. J Nucl Med. 2021. PMID: 34857663. doi:10.2967/jnumed.121.263082
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。